EURI B Stock Overview
Manufactures and sells diagnostic assays for the clinical laboratory and point-of-care settings, and point-of-care instrumentation for diagnostic applications in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
European Institute of Science AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.12 |
| 52 Week High | SEK 18.00 |
| 52 Week Low | SEK 1.40 |
| Beta | 2.22 |
| 11 Month Change | -15.20% |
| 3 Month Change | -36.53% |
| 1 Year Change | -81.07% |
| 33 Year Change | -98.26% |
| 5 Year Change | -99.02% |
| Change since IPO | -99.92% |
Recent News & Updates
Shareholder Returns
| EURI B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 5.0% | -5.8% | -2.1% |
| 1Y | -81.1% | 14.3% | 10.8% |
Return vs Industry: EURI B underperformed the Swedish Biotechs industry which returned 17.8% over the past year.
Return vs Market: EURI B underperformed the Swedish Market which returned 12.5% over the past year.
Price Volatility
| EURI B volatility | |
|---|---|
| EURI B Average Weekly Movement | 24.2% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: EURI B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: EURI B's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 2 | n/a | www.euris.org |
European Institute of Science AB (publ) manufactures and sells diagnostic assays for the clinical laboratory and point-of-care settings, and point-of-care instrumentation for diagnostic applications in Sweden. It primarily focuses on the diagnostic assays and instrumentation for canine, feline, and equine animals. The company’s products include TurboReader point-of-care instruments that performs measurements using disposable cuvettes; Canine C-Reactive (CRP) TurboReader assays for the quantitative determination of Canine CRP in dog serum or plasma; Feline Hp (Haptoglobin) TurboReader assay for determining Hp in cat serum or plasma; Feline SAA TurboReader assay for the determination of serum amyloid A (SAA) in cat serum or plasma; and Equine SAA TurboReader assay for determining SAA in horse serum or plasma.
European Institute of Science AB (publ) Fundamentals Summary
| EURI B fundamental statistics | |
|---|---|
| Market cap | SEK 3.97m |
| Earnings (TTM) | -SEK 2.58m |
| Revenue (TTM) | SEK 930.87k |
4.3x
P/S Ratio-1.5x
P/E RatioIs EURI B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EURI B income statement (TTM) | |
|---|---|
| Revenue | SEK 930.87k |
| Cost of Revenue | SEK 388.41k |
| Gross Profit | SEK 542.45k |
| Other Expenses | SEK 3.13m |
| Earnings | -SEK 2.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.38 |
| Gross Margin | 58.27% |
| Net Profit Margin | -277.62% |
| Debt/Equity Ratio | 0% |
How did EURI B perform over the long term?
See historical performance and comparison